1026 related articles for article (PubMed ID: 20386076)
61. Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.
Rawizza HE; Sax PE
AIDS Read; 2008 Sep; 18(9):466-72, 478-9. PubMed ID: 18828231
[TBL] [Abstract][Full Text] [Related]
62. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
63. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Kakuda TN; Wade JR; Snoeck E; Vis P; Schöller-Gyüre M; Peeters MP; Corbett C; Nijs S; Vingerhoets J; Leopold L; De Smedt G; Woodfall BJ; Hoetelmans RM
Clin Pharmacol Ther; 2010 Nov; 88(5):695-703. PubMed ID: 20881958
[TBL] [Abstract][Full Text] [Related]
64. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
Soon GH; Shen P; Yong EL; Pham P; Flexner C; Lee L
Antimicrob Agents Chemother; 2010 Jul; 54(7):2775-80. PubMed ID: 20385850
[TBL] [Abstract][Full Text] [Related]
65. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
[TBL] [Abstract][Full Text] [Related]
66. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
[TBL] [Abstract][Full Text] [Related]
67. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
[TBL] [Abstract][Full Text] [Related]
68. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
Moltó J; Valle M; Miranda C; Cedeño S; Negredo E; Barbanoj MJ; Clotet B
Antimicrob Agents Chemother; 2011 Jan; 55(1):326-30. PubMed ID: 21078942
[TBL] [Abstract][Full Text] [Related]
69. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Hulskotte EG; Feng HP; Xuan F; van Zutven MG; Treitel MA; Hughes EA; O'Mara E; Youngberg SP; Wagner JA; Butterton JR
Clin Infect Dis; 2013 Mar; 56(5):718-26. PubMed ID: 23155151
[TBL] [Abstract][Full Text] [Related]
70. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.
Podsadecki TJ; Vrijens BC; Tousset EP; Rode RA; Hanna GJ
HIV Clin Trials; 2008; 9(4):238-46. PubMed ID: 18753118
[TBL] [Abstract][Full Text] [Related]
71. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
72. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.
; Boyd MA; Kumarasamy N; Moore CL; Nwizu C; Losso MH; Mohapi L; Martin A; Kerr S; Sohn AH; Teppler H; Van de Steen O; Molina JM; Emery S; Cooper DA
Lancet; 2013 Jun; 381(9883):2091-9. PubMed ID: 23769235
[TBL] [Abstract][Full Text] [Related]
73. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
[TBL] [Abstract][Full Text] [Related]
74. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
[TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
Kakuda TN; Brochot A; Tomaka FL; Vangeneugden T; Van De Casteele T; Hoetelmans RM
J Antimicrob Chemother; 2014 Oct; 69(10):2591-605. PubMed ID: 24951533
[TBL] [Abstract][Full Text] [Related]
76. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
[TBL] [Abstract][Full Text] [Related]
77. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.
Calza L; Colangeli V; Magistrelli E; Bussini L; Conti M; Ramazzotti E; Mancini R; Viale P
HIV Med; 2017 Aug; 18(7):474-481. PubMed ID: 28116848
[TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
[TBL] [Abstract][Full Text] [Related]
79. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
Ofotokun I; Chuck SK; Binongo JN; Palau M; Lennox JL; Acosta EP
J Clin Pharmacol; 2007 Aug; 47(8):970-7. PubMed ID: 17615254
[TBL] [Abstract][Full Text] [Related]
80. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
